Company logo

GILD - Gilead Sciences, Inc.

NASDAQ -> Healthcare -> Drug Manufacturers—General
Foster City, United States
Type: Equity

GILD price evolution
GILD
(in millions $) 31 Jan 2024 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $6085 $5705 $5704 $4936
Short term investments $1179 $1159 $963 $936
Net receivables $4660 $4790 $4229 $4162
Inventory $1787 $1663 $1633 $1576
Total current assets $16085 $15980 $14287 $13456
Long term investments $1163 $1156 $1334 $1327
Property, plant & equipment $5317 $5572 $5540 $5479
Goodwill & intangible assets $34768 $35466 $36064 $36662
Total noncurrent assets $46040 $46393 $48050 $48420
Total investments $2342 $2315 $2297 $2263
Total assets $62125 $62373 $62337 $61876
Current liabilities
Accounts payable $550 $586 $622 $627
Deferred revenue
Short long term debt $1798 $1793 $4037 $2283
Total current liabilities $11280 $11945 $13964 $10528
Long term debt $23189 $23189 $21209 $22956
Total noncurrent liabilities $28096 $28186 $27279 $30409
Total debt $24987 $24982 $25246 $25239
Total liabilities $39376 $40131 $41243 $40937
Shareholders' equity
Retained earnings $16304 $16002 $15138 $15223
Other shareholder equity $28 $31 $10 -$20
Total shareholder equity $22833 $22314 $21158 $20997
(in millions $) 31 Jan 2024 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $6085 $5412 $5338 $5997
Short term investments $1179 $973 $1182 $1411
Net receivables $4660 $4777 $4493 $4892
Inventory $1787 $2820 $1618 $1683
Total current assets $16085 $15227 $14772 $15996
Long term investments $1163 $1245 $1309 $502
Property, plant & equipment $5317 $5475 $5121 $4967
Goodwill & intangible assets $34768 $37208 $41787 $41234
Total noncurrent assets $46040 $48728 $53180 $52411
Total investments $2342 $2218 $2491 $1913
Total assets $62125 $63171 $67952 $68407
Current liabilities
Accounts payable $550 $905 $705 $844
Deferred revenue
Short long term debt $1798 $2273 $1516 $2757
Total current liabilities $11280 $11237 $11610 $11397
Long term debt $23189 $22957 $25179 $28645
Total noncurrent liabilities $28096 $30725 $35278 $38789
Total debt $24987 $25230 $26695 $31402
Total liabilities $39376 $41962 $46888 $50186
Shareholders' equity
Retained earnings $16304 $15687 $16324 $14381
Other shareholder equity $28 $21209 $83 -$60
Total shareholder equity $22833 $21240 $21069 $18202
(in millions $) 31 Jan 2024 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue $7051 $6599 $6352
Cost of revenue $1565 $1442 $1401
Gross Profit $5486 $5157 $4951
Operating activities
Research & development $1457 $1407 $1447
Selling, general & administrative $1315 $1849 $1319
Total operating expenses $2863 $3492 $3247
Operating income $2623 $1665 $1704
Income from continuing operations
EBIT $2558 $1824 $1556
Income tax expense $146 $549 $316
Interest expense $232 $230 $230
Net income
Net income $2180 $1045 $1010
Income (for common shares) $2180 $1045 $1010
(in millions $) 31 Dec 2023 31 Dec 2022 31 Jan 2022 31 Dec 2020
Revenue
Total revenue $27116 $27281 $24689
Cost of revenue $6498 $5657 $4572
Gross Profit $20618 $21624 $20117
Operating activities
Research & development $5718 $4977 $5039
Selling, general & administrative $6090 $5673 $5151
Total operating expenses $13013 $14294 $16046
Operating income $7605 $7330 $4071
Income from continuing operations
EBIT $7856 $6775 $2687
Income tax expense $1247 $1248 $1580
Interest expense $944 $935 $984
Net income
Net income $5665 $4592 $123
Income (for common shares) $5665 $4592 $123
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income $1429 $2180 $1045 $1010
Operating activities
Depreciation $688 $684 $681 $640
Business acquisitions & disposals -$279 -$79 -$243 -$551
Stock-based compensation $201 $202 $198 $165
Total cash flows from operations $2169 $1755 $2338 $1744
Investing activities
Capital expenditures -$215 -$122 -$139 -$109
Investments -$233 -$34 -$100 -$161
Total cash flows from investing -$727 -$229 -$483 -$826
Financing activities
Dividends paid -$943 -$953 -$944 -$969
Sale and purchase of stock -$124 -$217 -$124 $97
Net borrowings $1 -$271
Total cash flows from financing -$1099 -$1519 -$1101 -$1406
Effect of exchange rate $37 -$6 $13 $13
Change in cash and equivalents $380 $1 $768 -$476
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income $5665 $4592 $6225 $123
Operating activities
Depreciation $2693 $2103 $2050 $1480
Business acquisitions & disposals -$1152 -$1797 -$1402 -$25742
Stock-based compensation $766 $637 $635 $643
Total cash flows from operations $8006 $9072 $11384 $8168
Investing activities
Capital expenditures -$585 -$728 -$579 -$650
Investments -$528 $60 -$987 $11948
Total cash flows from investing -$2265 -$2466 -$3131 -$14615
Financing activities
Dividends paid -$3809 -$3709 -$3605 -$3449
Sale and purchase of stock -$768 -$1087 -$377 -$1327
Net borrowings -$270 -$1500 -$4750 $5684
Total cash flows from financing -$5125 -$6469 -$8877 $770
Effect of exchange rate $57 -$63 -$35 $43
Change in cash and equivalents $673 $74 -$659 -$5634
Fundamentals
Market cap $90.97B
Enterprise value $109.87B
Shares outstanding 1.25B
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio 3.99
Book/Share 18.30
Cash/Share 4.88
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 1.72
Net debt/EBITDA N/A
Current ratio 1.43
Quick ratio 1.27